Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:35:19 2025-07-10 am EDT			Pre-market 01:47:39 am
27.78 ^EUR	+1.65%		27.70	-0.29%

Jul. 10	Bayer Receives U.K. Approval for Hot Flashes Treatment	DJ
Jul. 10	Bayer receives approval for Lynkuet(TM) (Elinzanetant) in UK	RE

Goldman Sachs Upgrades Bayer to Buy, Raises PT

Published on 06/05/2025 at 08:39

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Bayer AG

Bayer Receives U.K. Approval for Hot Flashes Treatment	Jul. 10	DJ
Bayer receives approval for Lynkuet(TM) (Elinzanetant) in UK	Jul. 10	RE
Bayer Rules Out Further Plant Closures in Germany After Frankfurt Exit	Jul. 10	RE
Reaches socially acceptable agreements for the withdrawal from Frankfurt/Main site and secures remaining company sites in Germany until 2030	Jul. 10	RE
Bayer Submits Gadoquatrane for EU Approval to Offer Lower-dose MRI Contrast Agent	Jul. 10	MT
Bayer: application for approval of its contrast agent	Jul. 10	CF
Bayer Seeks EU Approval for Low-Dose MRI Contrast Agent Gadoquatrane	Jul. 10	MT
Bayer files for EU approval of gadoquatrane	Jul. 10	RE
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	Jul. 09	RE
Bayer Wins Maiden Approval For Menopausal Hot Flashes Medication From UK Regulator	Jul. 09	MT
German Equities Jump Amid EU-US Trade Deal Optimism	Jul. 08	MT
MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms caused by menopause	Jul. 08	RE
UK Clears Bayer Medicine for Menopause-related Hot Flashes	Jul. 08	MT
Bayer Treats First Patient in Early-stage Trial for Retinal Disorder Drug Candidate	Jul. 08	MT
Bayer Ag and BlueRock Therapeutics LP Announces First Patient Receives Investigational Therapy in Phase 1/2a Clinical Trial of OpCT-001 for the Treatment of Primary Photoreceptor Diseases	Jul. 08	CI
Bayer: testing OpCT-001, an experimental cell therapy	Jul. 08	CF
Vincerx Pharma, Inc. and Vnrx, Inc Announces Termination of License Agreement with Bayer Aktiengesellschaft and Bayer Intellectual Property Gmbh	Jul. 07	CI
BAYER AG : JP Morgan gives a Neutral rating	Jul. 07	ZD
BAYER AG : Goldman Sachs keeps its Buy rating	Jul. 04	ZD
General Mills changing Nature Valley labels after lawsuit's herbicide claim	Jul. 01	RE
Bayer Announces Executive Changes for North America	Jul. 01	CI
BAYER AG : UBS reaffirms its Neutral rating	Jul. 01	ZD
BAYER AG : JP Morgan reiterates its Neutral rating	Jun. 30	ZD
European shares see monthly declines as markets eye trade developments	Jun. 30	RE
BAYER AG : Jefferies remains Neutral	Jun. 30	ZD

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

90,885

Sector

Pharmaceuticals

Calendar

Aug. 06 - Q2 2025 Earnings Release

More about the company